Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (1648)	1/9/2006 1:27:57 PM
From: tuck	Read Replies (1) \| Respond to of 1826

Here's a threat to Aloxi I was unaware off, and it's perhaps not that far off: >>SOUTH SAN FRANCISCO, Calif. (AP) -- Hana Biosciences Inc. said Monday that its oral spray for chemotherapy-induced nausea and vomiting proved equivalent to an existing product in a clinical trial. The study included 32 patients who received either Hana's Zensana drug or GlaxosmithKline's Zofran. Hana said it is completing additional trials needed for approval of the therapy before applying to the Food and Drug Administration in the second quarter of 2006. Hana expects to launch Zensana in 2007. The company's shares rose 15 cents, or 2.5 percent, to $6.10 in midday trading on the American Stock Exchange. Nausea is a common side effect of the chemotherapy drugs taken by most cancer patients.<< Cheers, Tuck

To: IRWIN JAMES FRANKEL who wrote (1648)	1/12/2006 9:26:15 AM
From: sammaster	Respond to of 1826

aloxi sales to outpatient oncology offices and hospital based "outpatient" chemo center sales would not decline as they receive higher reibursement for aloxi over generic zofran... according to their presentations this seems to be their main market right now so these sales are "protected" from generic zofran.. i do agree that on the inpatient side that hospitals will switch wholeheartedly to cheaper generic zofran.. it seems like oral aloxi tabs when they get approval will have pressure of cheaper outpatient scripts of zofran.. however if aloxi truly does control nausea better and longer and truly reduces post op nausea recovery or inpatient chemo recovery and thus reduce length of stay in hospital then aloxi would be preffered over generic zofran... it would take a lot of doses of cost savings from generic zofran to make up for the cost of 1 patient staying in the hospital 1 more day because of nausea/vomitting...